Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Veracyte (VCYT) EBIAT (2016 - 2026)

Veracyte's EBIAT history spans 14 years, with the latest figure at $41.1 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 704.79% to $41.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.4 million, a 174.89% increase, with the full-year FY2025 number at $66.4 million, up 174.89% from a year prior.
  • EBIAT hit $41.1 million in Q4 2025 for Veracyte, up from $19.1 million in the prior quarter.
  • Over the last five years, EBIAT for VCYT hit a ceiling of $41.1 million in Q4 2025 and a floor of -$41.9 million in Q1 2021.
  • Historically, EBIAT has averaged -$4.8 million across 5 years, with a median of -$8.2 million in 2023.
  • Biggest five-year swings in EBIAT: tumbled 636.03% in 2023 and later surged 704.79% in 2025.
  • Tracing VCYT's EBIAT over 5 years: stood at -$10.5 million in 2021, then soared by 63.49% to -$3.8 million in 2022, then tumbled by 636.03% to -$28.3 million in 2023, then surged by 118.07% to $5.1 million in 2024, then skyrocketed by 704.79% to $41.1 million in 2025.
  • Business Quant data shows EBIAT for VCYT at $41.1 million in Q4 2025, $19.1 million in Q3 2025, and -$980000.0 in Q2 2025.